Cancer Genetics, Inc. Launches Webinar Series to Drive Awareness and Adoption of Its Proprietary DNA-Based Cervical Cancer Di...
January 29 2014 - 7:20AM
Cancer Genetics, Inc. (Nasdaq:CGIX) ("CGI" or the "Company"), an
emerging leader in DNA-based diagnostics, is launching a webinar
series to inform clinicians and pathologists of the value of its
proprietary DNA-based test for cervical cancer, FHACT™, which is
processed in the Company's CLIA certified, clinical laboratory. The
webinar series will begin on Friday, January 31, at 9:30 a.m. ET
and will be available again on Thursday, February 6, at 9:30 a.m.
ET.
CGI's webinar series, "An introduction to FHACT™: the FISH-based
HPV-Associated Cancer Test," was designed by Jane Houldsworth, PhD,
Vice President of R&D at CGI, to better inform clinicians and
pathologists about the value of using FHACT™ to help in triaging
women with low grade cytological abnormalities prior to
colposcopy.
Dr. Houldsworth led the research study of FHACT™ at CGI in
collaboration with the National Cancer Institute (NCI). Data from
the study was published in the July 2013 issue of
Gynecologic Oncology
(http://dx.doi.org/10.1016/j.ygyno.2013.06.005) where the
genetic regions assessed in FHACT™ were found to be associated with
severity of cervical lesions.
"About 2 million women are referred each year in the U.S. to
undergo colposcopy, based on abnormal cytology and HPV testing, and
of these significantly less than half require additional medical
follow-up for diagnosed precancerous and cancerous lesions. Thus,
there is a need to identify with greater efficiency women who are
at risk to have such medically actionable lesions prior to referral
for colposcopy. FHACT™ has the potential to reduce the health-care
burden associated with cervical cancer and requires no further
sample from the patient," commented Dr. Houldsworth. "The potential
of FHACT™ to provide more accurate and earlier detection of
HPV-associated cancers and pre-cancers can save valuable time in
the testing process, while creating substantial cost savings for
the healthcare system."
Although approximately 90% of HPV infections will be cleared
within 2 years, a minority of precancerous lesions will progress to
a higher-grade lesion. Women diagnosed with LSIL (low-grade
squamous intraepithelial lesions) have a marginally higher risk of
progression, and current high-risk HPV testing does not provide
additional benefit in risk assessment for cancer. It is in these
clinical settings where the integration of additional genetic
biomarkers in the triage process is needed to limit unnecessary
colposcopies and excisional procedures and to identify those women
with lesions that are at risk of progressing to a higher grade
cervical cancer.
CGI's non-invasive FHACT™ test provides genomic information
directly from leftover liquid cytology and does not require
additional office visits. By using a unique combination of four
genetic biomarkers, the FHACT™ test increases the sensitivity of
detection of cells that show genomic abnormalities.
To register for the webinar series, please visit:
http://www.cgifhact.com/webinar/.
The webinar series will be hosted by CGI's Associate Product
Manager, Alexandra Arndt, BS, CG (ASCP). Registered attendees of
the live webinars can participate in Q&A sessions with Ms.
Arndt. For those unable to attend the live events, the webinar
series will be available for on demand viewing.
About Cancer Genetics:
Cancer Genetics, Inc. is an emerging leader in DNA-based cancer
diagnostics, servicing some of the most prestigious medical
institutions in the world. Our tests target cancers that are
difficult to diagnose and predict treatment outcomes. These cancers
include hematological, urogenital and HPV-associated cancers. We
also offer a comprehensive range of non-proprietary
oncology-focused tests and laboratory services that provide
critical genomic information to healthcare professionals, as well
as biopharma and biotech companies. Our state-of-the-art reference
lab is focused entirely on maintaining clinical excellence and is
both CLIA certified and CAP accredited and has licensure from
several states including New York State. We have established strong
research collaborations with major cancer centers such as Memorial
Sloan-Kettering, The Cleveland Clinic, Mayo Clinic and the National
Cancer Institute. For further information, please
see www.cancergenetics.com.
Forward Looking Statements:
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. All statements pertaining to future financial and/or
operating results, future growth in research, technology, clinical
development and potential opportunities for Cancer Genetics, Inc.
products and services, along with other statements about the future
expectations, beliefs, goals, plans, or prospects expressed by
management constitute forward-looking statements. Any statements
that are not historical fact (including, but not limited to,
statements that contain words such as "will," "believes," "plans,"
"anticipates," "expects," "estimates") should also be considered to
be forward-looking statements. Forward-looking statements involve
risks and uncertainties, including, without limitation, risks
inherent in the development and/or commercialization of potential
products, uncertainty in the results of clinical trials or
regulatory approvals, need and ability to obtain future capital,
maintenance of intellectual property rights and other risks
discussed in the Company's Form 10-Q for the quarter ended
September 30, 2013 and other filings with the Securities and
Exchange Commission. These forward-looking statements speak only as
of the date hereof. Cancer Genetics disclaims any obligation to
update these forward-looking statements.
CONTACT: Investor Relations
RedChip Companies, Inc.
Jon Cunningham, 800-733-2447, ext. 107
jon@redchip.com
Cancer Genetics (NASDAQ:CGIX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Cancer Genetics (NASDAQ:CGIX)
Historical Stock Chart
From Jul 2023 to Jul 2024